Epigallocatechin-3-gallate improves Dermatophagoides pteronissinus extract-induced atopic dermatitis-like skin lesions in NC/Nga mice by suppressing macrophage migration inhibitory factor

International Immunopharmacology

Volumn 8, Issue 9, 2008, Pages 1172-1182

  Noh, Sun Up ^a   Cho, Eun Ah ^a   Kim, Hyung Ok ^a   Park, Young Min ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Atopic dermatitis; Cytokines; Epigallocatechin 3 gallate; Macrophage migration inhibitory factor; NC Nga mice

Indexed keywords

CYTOKINE; EPIGALLOCATECHIN GALLATE; GAMMA INTERFERON; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; MACROPHAGE MIGRATION INHIBITION FACTOR; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; TH1 CELL; THICKNESS;

ANIMALS; ANTIGENS, DERMATOPHAGOIDES; CATECHIN; CYTOKINES; DERMATITIS, ATOPIC; EAR, EXTERNAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; TACROLIMUS;

EID: 46349101999     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.04.002     Document Type: Article

References (46)

1. Hsu S. Green tea and the skin. J Am Acad Dermatol (2005) 1049-1059
2. Trompezinski S., Denis A., Schmitt D., and Viac J. Comparative effects of polyphenols from green tea (EGCG) and soybean (genistein) on VEGF and IL-8 release from normal human keratinocytes stimulated with the proinflammatory cytokine TNFα. Arch Dermatol Res 295 (2003) 112-116
3. Huang C.C., Fang J.Y., Wu W.B., Chiang H.S., Wei Y.J., and Hung C.F. Protective effects of (-)-epicatechin-3-gallate on UVA-induced damage in HaCaT keratinocytes. Arch Dermatol Res 296 (2005) 473-481
4. Afaq F., Ahmad N., and Mukhtar H. Suppression of UVB-induced phosphorylation of mitogen-activated protein kinases and nuclear factor kappa B by green tea polyphenol in SKH-1 hairless mice. Oncogene 22 (2003) 9254-9264
5. Hsu S., Dickinson D., Borke J., Walsh D.S., Wood J., Qin H., et al. Green tea polyphenol induces caspase 14 in epidermal keratinocytes via MAPK pathways and reduces psoriasiform lesions in the flaky skin mouse model. Exp Dermatol 16 (2007) 678-684
6. Katiyar S.K., and Mukhtar H. Green tea polyphenol (-)-epigallocatechin-3-gallate treatment to mouse skin prevents UVB-induced infiltration of leukocytes, depletion of antigen-presenting cells, and oxidative stress. J Leukoc Biol 69 (2001) 719-726
7. Leung D.Y., Boguniewicz M., Howell M.D., Nomura I., and Hamid Q.A. New insights into atopic dermatitis. J Clin Invest 113 (2004) 651-657
8. Abramovits W. Atopic dermatitis. J Am Acad Dermatol 53 (2005) S86-S93
9. Boguniewicz M., and Leung D.Y. 10. Atopic dermatitis. J Allergy Clin Immunol 117 (2006) S475-S480
10. Beltrani V.S. Suggestions regarding a more appropriate understanding of atopic dermatitis. Curr Opin Allergy Clin Immunol 5 (2005) 413-418
11. Allam J.P., Bieber T., and Novak N. Recent highlights in the pathophysiology of atopic eczema. Int Arch Allergy Immunol 136 (2005) 191-197
12. Allam J.P., and Novak N. The pathophysiology of atopic eczema. Clin Exp Dermatol 31 (2006) 89-93
13. Novak N., and Bieber T. The role of dendritic cell subtypes in the pathophysiology of atopic dermatitis. J Am Acad Dermatol 53 (2005) S171-S176
14. Shimizu T., Abe R., Ohkawara A., Mizue Y., and Nishihira J. Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis. Biochem Biophys Res Commun 240 (1997) 173-178
15. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 37 (2005) 65-73
16. Baugh J.A., and Bucala R. Macrophage migration inhibitory factor. Crit Care Med 30 (2002) S27-S35
17. de Jong Y.P., Abadia-Molina A.C., Satoskar A.R., Clarke K., Rietdijk S.T., Faubion W.A., et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2 (2001) 1061-1066
18. Takase H., Sugita S., Rhee D.J., Imai Y., Taguchi C., Sugamoto Y., et al. The presence of macrophage migration inhibitory factor in human trabecular meshwork and its upregulatory effects on the T helper 1 cytokine. Invest Ophthalmol Vis Sci 43 (2002) 2691-2696
19. Larson D.F., and Horak K. Macrophage migration inhibitory factor: controller of systemic inflammation. Crit Care 10 (2006) 138
20. Calandra T., Bernhagen J., Metz C.N., Spiegel L.A., Bacher M., Donnelly T., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377 (1995) 68-71
21. Morand E.F. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 35 (2005) 419-426
22. Rosengren E., Aman P., Thelin S., Hansson C., Ahlfors S., Bjork P., et al. The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 417 (1997) 85-88
23. Molnar V., and Garai J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int Immunopharmacol 5 (2005) 849-856
24. Matsuda H., Watanabe N., Geba G.P., Sperl J., Tsudzuki M., Hiroi J., et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9 (1997) 461-466
25. Shiohara T., Hayakawa J., and Mizukawa Y. Animal models for atopic dermatitis: are they relevant to human disease?. J Dermatol Sci 36 (2004) 1-9
26. Kang J.S., Lee K., Han S.B., Ahn J.M., Lee H., Han M.H., et al. Induction of atopic eczema/dermatitis syndrome-like skin lesions by repeated topical application of a crude extract of Dermatophagoides pteronyssinus in NC/Nga mice. Int Immunopharmacol 6 (2006) 1616-1622
27. Stratton S.P., Bangert J.L., Alberts D.S., and Dorr R.T. Dermal toxicity of topical (-)epigallocatechin-3-gallate in BALB/c and SKH1 mice. Cancer Lett 158 (2000) 47-52
28. Tanaka A., Muto S., Jung K., Itai A., and Matsuda H. Topical application with a new NF-kappaB inhibitor improves atopic dermatitis in NC/NgaTnd mice. J Invest Dermatol 127 (2007) 855-863
29. Zhao Y., Shimizu T., Nishihira J., Koyama Y., Kushibiki T., Honda A., et al. Tissue regeneration using macrophage migration inhibitory factor-impregnated gelatin microbeads in cutaneous wounds. Am J Pathol 167 (2005) 1519-1529
30. Sasakawa T., Higashi Y., Sakuma S., Hirayama Y., Sasakawa Y., Ohkubo Y., et al. Topical application of FK506 (tacrolimus) ointment inhibits mite antigen-induced dermatitis by local action in NC/Nga mice. Int Arch Allergy Immunol 133 (2004) 55-63
31. Shimizu T., Abe R., Ohkawara A., and Nishihira J. Increased production of macrophage migration inhibitory factor by PBMCs of atopic dermatitis. J Allergy Clin Immunol 104 (1999) 659-664
32. Bacher M., Metz C.N., Calandra T., Mayer K., Chesney J., Lohoff M., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci U S A 93 (1996) 7849-7854
33. Leng L., Metz C.N., Fang Y., Xu J., Donnelly S., Baugh J., et al. MIF signal transduction initiated by binding to CD74. J Exp Med 197 (2003) 1467-1476
34. Calandra T., Bernhagen J., Mitchell R.A., and Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179 (1994) 1895-1902
35. Calandra T., and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3 (2003) 791-800
36. Yanagi T., Kodama K., Yoshihisa Y., Shimizu H., and Shimizu T. Macrophage migration inhibitory factor in zinc-allergic systemic contact dermatitis. Cytokine 35 (2006) 270-274
37. Shimizu T., Abe R., Nishihira J., Shibaki A., Watanabe H., Nakayama T., et al. Impaired contact hypersensitivity in macrophage migration inhibitory factor-deficient mice. Eur J Immunol 33 (2003) 1478-1487
38. Steinhoff M., Meinhardt A., Steinhoff A., Gemsa D., Bucala R., and Bacher M. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br J Dermatol 141 (1999) 1061-1066
39. Shimizu T., Nishihira J., Mizue Y., Nakamura H., Abe R., Watanabe H., et al. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 116 (2001) 989-990
40. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci U S A 102 (2005) 14410-14415
41. Nakamaru Y., Oridate N., Nishihira J., Takagi D., Furuta Y., and Fukuda S. Macrophage migration inhibitory factor (MIF) contributes to the development of allergic rhinitis. Cytokine 31 (2005) 103-108
42. Wang B., Huang X., Wolters P.J., Sun J., Kitamoto S., Yang M., et al. Cutting edge: deficiency of macrophage migration inhibitory factor impairs murine airway allergic responses. J Immunol 177 (2006) 5779-5784
43. Flaster H., Bernhagen J., Calandra T., and Bucala R. The macrophage migration inhibitory factor-glucocorticoid dyad: regulation of inflammation and immunity. Mol Endocrinol 21 (2007) 1267-1280
44. Fingerle-Rowson G., Koch P., Bikoff R., Lin X., Metz C.N., Dhabhar F.S., et al. Regulation of macrophage migration inhibitory factor expression by glucocorticoids in vivo. Am J Pathol 162 (2003) 47-56
45. Orita M., Yamamoto S., Katayama N., and Fujita S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr Pharm Des 8 (2002) 1297-1317
46. Lubetsky J.B., Dios A., Han J., Aljabari B., Ruzsicska B., Mitchell R., et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277 (2002) 24976-24982